Introduction: Cardiac cell-cell junctions play important roles in maintaining cardiac integrity linking single cardiomyocytes into a single functioning syncytium. There are three main types of cell junctions in the heart: gap junctions (GJ), desmosomes (D) and adherens junctions (AJ). Mutations in the proteins which make-up these junctions are known to cause arrhythmogenic right ventricular cardiomyopathy (ARVC). Pathological features include progressive replacement of right ventricular cardiac muscle with fibrofatty tissue. This can lead to heart failure and life threatening arrhythmias. During normal development of the mammalian heart, protein components of AJ and D gradually fuse to form composite junctions at the intercalated discs, also called areae compositae (singular, area composita, AC). In contrast, the adult heart of lower vertebrates, including the zebrafish, may have few or no AC type junctions. The detailed structure of cardiomyocyte cell-cell junctions in the adult zebrafish heart remain poorly defined and their role in normal development, growth and response to injury have yet to be studied. This thesis will examine the hypothesis that localisation and distribution of myocardial cell-cell junction proteins are crucial in normal myocardial development and in endogenous cardiac regeneration and repair following injury. This will be achieved by understanding the normal development of cell-cell junction proteins in zebrafish from embryonic to adulthood. These findings will then be analysed in comparison to cell-cell junction proteins localisation and distribution in early and late mammalian (mouse and human) myocardium. Once a normal pattern of cell-cell junction proteins will be established, the localisation of cell-cell junction proteins in plakologbin mutant zebrafish model for cardiomyopathy will be studied to understand the distribution and localisation of these proteins in disease manifestation. This model will then be used to test if localisation of cell-cell junction proteins plays an important in cardiac repair following injury by using embryonic laser injury model, this will be further tested by drug intervention study to investigate underlying pathways such as Wnt signalling pathway. Methods: Myocardial cell-cell junctions were assessed using immunohistochemistry in embryonic, juvenile and adult zebrafish hearts and in foetal and adult human hearts. The Plakoglobin mutant zebrafish line (UAS:Gal-4:Plakoglobin Naxos; named as PGNx) was characterised using various functional and morphological assessments including histology, echocardiography and MRI scanning. Similar studies were undertaken in PGNx mutants at different developmental stages. A pharmacological intervention study, using a GSK-3 inhibitor, was carried out in PGNx mutants followed by cardiac structural and functional assessments. Laser-induced cardiac trauma was used to assess the response to injury and repair in normal and PGNx embryos following treatment with the GSK3 inhibitor drug. Results: Cell-cell junction patterning in the embryonic, juvenile and adult zebrafish heart shows a characteristic pearl string appearance of desmoplakin and β-catenin labelled distinct disc shaped AJ. Human foetal heart showed small distinct D and AJ, while the adult human heart had features consistent with AC type junctions. PGNx fish showed reduced ventricle ejection fraction, dilatation of the atrium, reduced amplitude of wall motion and ventricle relaxation velocity compared to age-matched controls. Echocardiography and MRI imaging confirmed severe atrial dilatation and restrictive ventricle physiology in adult fish. The cell-cell junction proteins were over-expressed in the zebrafish PG mutant (PGNx) hearts compared to age-matched controls. Drug studies using a GSK-3β inhibitor showed complete recovery of cardiac function and partial recovery of heart structure. Cardiac injury studies, using laser, showed failure of repair in PGNx embryos compared to age-matched controls. The GSK3 inhibitor failed to improve the functional response following heart laser injury. Conclusions: Cell-cell junctions are distributed abundantly around cardiomyocytes in the zebrafish heart during early development and into adulthood. In contrast to previous studies in adult mammalian heart, there was no evidence of AC type junctions in adult zebrafish cardiomyocytes. The mutant zebrafish line showed restrictive cardiac physiology and abnormal cardiac structure confirming the key role played by plakoglobin in the normal heart development. This is further supported by evidence showing failure of repair in PGNx mutant embryos after injury. Drug treatment with a GSK-3 inhibitor highlights a potentially novel therapeutic pathway for treatment of ARVC involving Wnt signalling.

An accumulation of sudden unexpected cardiac deaths (SUCD) occurred in young Swedish orienteers, most of whom were elite athletes. From 1979 to 1992 the incidence in 18 to 34 year old male elite orienteers ranked on the national level the same year as death was calculated to 30 (per 100,000), which represents a 20 to 40 fold increase from the expected rate. From 1989 to 1992, the incidence was 50. There were, however, no indications on any similar clusters of SUCD in other sports. A special program to alter behaviour in orienteers was implemented in 1992-1993, after which there have been no more cases of SUCD in orienteers below 35 years of age. A histopathological re-evaluation of 16 cases of SUCD revealed myocarditis in 75% of these cases. In parallel, four of those cases also had changes mimicing arrhythmogenic right ventricular cardiomyopathy (ARVC). The combination of an increased incidence and myocarditis suggested that infection may be a pathogenetic factor. A broad search for different microorganisms in archival sera from five cases and tissues from the autopsies in two of those cases revealed the only common finding that all had antibodies to Chlamydia pneumoniae. DNA from C. pneumoniae was detected in the lung and heart in one of two cases. The intimate contact with nature of orienteers suggested possible zoonotic/vectorborne pathogens. Bartonella is such a pathogen and known to cross-react with C. pneumoniae. The use of PCR to test for DNA from the gltA gene of Bartonella in the two formerly mentioned cases of SUCD, and in three additional cases, gave positive bands from the hearts in four cases and the lung in a fifth case. The PCR products were sequenced and found to be identical to B. henselae in three cases and almost identical to B. quintana in the remaining two cases. Four of the five cases had antibodies to Bartonella when using micro immunofluorescence test with the antigens B. henselae, B. quintana, and B. elizabethae. The total prevalence of antibodies to Bartonella was 31% in 1,136 elite orienteers vs. 6.8% in 322 healthy blood donors (p<0.001), suggesting widespread exposure in the elite. It is hypothesized that subacute or reactivated Bartonella infection has a pathogenetic role in SUCD in orienteers, and may be involved in the development of ARVC-like disease.

No description available.

Atrial fibrillation is the most prevalent arrhythmia worldwide and remains one of the major causes of morbidity and mortality. Atrial fibrillation is an arrhythmia that has a various etiology and takes number of clinical forms. Due to the heterogenity of atrial fibrillation, it is necessary to individualize the optimal treatment strategy, ie conservative pharmacological therapy or interventional therapy as catheter ablation. Inncorrect indication of catheter ablation of atrial fibrillation leads to low success rate of the procedure and increases the risk of the procedure. The success rate of catheter ablation of atrial fibrillation depends on many clinical parameters, including the size and volume of the left atrium and the presence of pathological tissue in the atrial myocardium. In everyday practice, echocardiography (2D-echocardiography) is the most dominant method in estimation of the left atrial parameters, for it's simplicity, non- invasiveness, financial costs and the absence of ionizing radiation. Different methods for assesment of left atrial parameters are cardiac CT, cardiac magnetic resonance imaging and methods of 3-D echocardiography or 3-D angiography. The results of the present studies show that in patients with non-valvular atrial fibrillation who are indicated for catheter...

Introduction : La cardiopathie arythmogène du ventricule droit (CAVD) est une pathologie d’origine génétique se traduisant par un remplacement cicatriciel qui affecte de façon prédominante le ventricule droit (VD). Le diagnostic est complexe car il repose sur un ensemble de critères cliniques plutôt que sur un seul test diagnostic. L’atteinte du VD se traduit de façon prédominante par des arythmies ventriculaires qui peuvent parfois conduire à la complication la plus redoutée de cette affection : la mort subite. La prédiction et la prévention de celle-ci sont des enjeux cruciaux de la prise en charge de cette maladie. Objectifs : Ce travail vise à améliorer la prise en charge des patients atteints de CAVD de deux façons distinctes. Premièrement, en tentant de faciliter le diagnostic par la validation des critères diagnostiques en vigueur. Deuxièmement, en améliorant la stratification du risque d’arythmie ventriculaires soutenues et plus spécifiquement celui de la mort subite et des arythmies potentiellement mortelles (tachycardie ventriculaire > 250 bpm, fibrillation ventriculaire) en créant des modèles de prédiction du risque permettant de déterminer le risque individuel de chaque patient. Résultats : Article 1 - Un total de 407 patients consécutifs référés pour une résonnance magnétique cardiaque pour suspicion de CAVD ont été inclus. De ceux-ci, 66 (16%) ont reçu un diagnostic définitif selon le critère de référence établi pour cette étude: le consensus d’un panel d’experts. Globalement, les critères performent bien avec une sensibilité et spécificité à 92%. Cependant, certains critères tels l’ECG haute amplitude (SAECG) et certains critères reliés à l’histoire familiale ne sont pas discriminants. Le retrait de ces critères pourrait réduire le nombre de faux positifs sans pour autant augmenter le nombre de faux négatifs (net reclassification improvement de 4,3%, p=0,019). De plus, la combinaison des critères électrocardiographiques et de la présence d’arythmies ventriculaires a une sensibilité de 100%, ce qui peut faciliter dans certains cas le dépistage en limitant la nécessité de recourir à l’imagerie. Pour les articles 2 et 3, une base de données incluant des patients avec un diagnostic définitif de CAVD a été assemblée à partir de bases de données provenant de six pays (Canada, États-Unis, Pays-Bas, Suède, Norvège, Suisse). Article 2 - Un total de 528 patients sans histoire antérieure d’arythmies ventriculaires soutenues a été inclus pour développer un modèle de prédiction de risque. De ceux-ci, 146 (27,7%) ont subi un événement arythmique durant un suivi médian de 4,8 ans. Des huit prédicteurs initialement identifiés (âge inférieur au diagnostic, sexe masculin, syncope cardiaque récente, nombre de dérivations avec des inversions des ondes T, fardeau d’extrasystoles ventriculaires (ESV) en 24h, tachycardie ventriculaire non-soutenue et fractions d’éjection des ventricules gauche et droit), sept ont été retenus dans le modèle, excluant seulement la fraction d’éjection du ventricule gauche (FEVG). Le modèle peut distinguer adéquatement entre les patients avec et sans événement (C-index de 0,77) avec un optimisme minimal (courbe de calibration de 0,93). L’utilisation de cet algorithme permettrait de réduire l’utilisation de défibrillateurs implantables de 20% par rapport à l’algorithme du consensus le plus largement utilisé. Article 3 - Une cohorte de 864 patients incluant à la fois ceux avec et sans histoire antérieure d’arythmie ventriculaire soutenue a été assemblée. Durant un suivi médian de 5,75 ans, 93 patients ont eu un épisode d’arythmie rapide selon la définition préalablement établie. Des huit facteurs de risque cités ci-haut, seulement quatre ont été retenus dans le modèle : l’âge plus jeune au diagnostic, sexe masculin, fardeau d’ESV en 24h et nombre de dérivations avec des inversions des ondes T. Fait à noter, les événements antérieurs ne se sont pas avérés prédicteurs d’arythmies potentiellement mortelles subséquentes. Le modèle peut distinguer adéquatement entre les patients avec et sans événement (C-index de 0,74) et présente un optimisme minimal avec une courbe de calibration de 0,95. Conclusion : Bien que les critères diagnostiques en vigueur pour la CAVD aient une performance adéquate, ceux-ci peuvent être simplifiés et améliorés par le retrait de certains de ces critères. L’absence de critères électrocardiographiques combinés et d’arythmies ventriculaires peut exclure une CAVD, ce qui peut en simplifier le dépistage. Chez les patients atteints de CAVD, la prédiction du risque et la sélection des patients pour l’implantation d’un défibrillateur peuvent être facilités grâce à deux modèles complémentaires de prédiction du risque permettant de prédire les événements arythmiques soutenus dans le premier et plus spécifiquement les arythmies ventriculaires potentiellement mortelles dans le deuxième. Ces outils sont particulièrement utiles dans une approche de prise de décision partagée. / Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic pathology resulting in a fibro-fatty replacement predominantly affecting the right ventricle. The diagnosis is complex and is based on a set of clinical criteria. Involvement of the right ventricle predominantly results in ventricular arrhythmias which constitutes the most common presentation but can also lead to the most feared consequence: sudden cardiac death. Predicting and preventing this catastrophic outcome are crucial in the management of this disease. Objectives: This work aims to improve the management of patients with ARVC in two distinct ways. First, by attempting to facilitate the diagnosis by validating the currently used diagnostic criteria. Second by improving risk stratification for sustained ventricular arrhythmias and specifically life-threatening ventricular arrhythmias (LTVA defined as ventricular tachycardia > 250 bpm, ventricular fibrillation, and sudden death) by creating risk prediction models to derive individual risk. Results: Manuscript 1: a total of 407 patients referred for cardiac magnetic resonance for suspected ARVC were consecutively enrolled. Of these, 66 (16%) received a definitive diagnosis of ARVC by the determined endpoint: the consensus of an expert panel. Overall, the criteria performed well with a sensitivity and specificity of 92%. However, certain criteria such as the signal averaged electrocardiogram (SAECG) and certain criteria related to family history failed to discriminate. Removing these criteria could reduce false positives without increasing false negatives (net reclassification improvement of 4.3%, P = 0.019). In addition, the electrocardiographic criteria and the presence of arrhythmia had a sensitivity of 100%, which can facilitate screening in some cases by making imaging optional. For manuscripts 2 and 3, a cohort including patients with a definitive diagnosis of ARVC was assembled from databases in 6 countries (Canada, United States, Netherlands, Sweden, Norway, Switzerland). Manuscript 2: a total of 528 patients with no previous history of sustained ventricular arrhythmias were included to develop a risk prediction model. Of these, 146 (27.7%) had an arrhythmic event during a median follow-up of 4.8 years. Of the eight predictors initially identified (younger age at diagnosis, male sex, recent cardiac syncope, the number of leads with T wave inversions on the ECG, burden of extrasystoles in 24 hours, non-sustained ventricular tachycardia and left and right ventricular ejection fraction), seven were retained in the model, excluding only left ventricular ejection fraction. The model adequately distinguished between patients with and without an arrhythmic event (C-index of 0.77) with minimal optimism (calibration slope of 0.93). Using this prediction model would reduce the use of defibrillators by 20% compared with the most commonly used consensus based on a risk factor approach. Manuscript 3: a cohort including both patients with and without a prior history of ventricular arrhythmia of 864 patients was assembled. During a follow-up of 5.75 years, 93 patients had an LTVA as defined above. Of the 8 risk factors cited above, only 4 were retained in the model: younger age at diagnosis, male sex, burden of extrasystoles in 24 hours and number of leads with T-wave inversions. Importantly, previous events are not predictive of these subsequent life-threatening arrhythmias. The model adequately distinguished between patients with and without an event (C-index of 0.74) with minimal optimism (calibration slope of 0.95). Conclusion: Although the current diagnostic criteria for ARVC perform adequately, they can be simplified and improved by removing underperforming individual criteria. The absence of any ECG criteria and ventricular arrhythmias may rule out ARVC, which may simplify screening. In patients with ARVC, risk prediction and patient selection for a defibrillator can be facilitated by two complementary risk prediction models for sustained arrhythmic events or more specifically for LTVA. These tools are particularly useful in a shared decision-making approach for implantable cardioverter defibrillator implantation.

[ES] Las enfermedades cardiovasculares son una de las principales causas de mortalidad y morbilidad en el mundo. Entre las arritmias más comunes en adultos destaca la Fibrilación Auricular (FA), presentando una tendencia de crecimiento muy significativa, sobre todo en población de edad avanzada o con trastornos de obesidad. En el otro extremo, nos encontramos con la Miocardiopatía Arritmogénica (MCA), considerada una enfermedad rara con una prevalencia de 1:2000-5000 pero con gran afectación entre familiares directos, causante de muerte súbita cardiaca (MSC), y con un diagnóstico clínico complicado. Más allá de la FA o la MCA, existe una amplia variedad de patologías derivadas de una disfunción en la activación y conducción eléctrica del corazón. Para todas ellas, el electrocardiograma (ECG) continúa figurando como la primera y principal técnica de diagnóstico clínico, siendo una herramienta fundamental de cribado y detección de patologías relativamente económica y ampliamente accesible. Sin embargo, el diagnóstico preciso a partir de la interpretación del ECG requiere de médicos experimentados, siendo ésta una tarea que consume recursos, tiempo y que además está sujeta a la variabilidad entre observadores. Respecto a las afecciones cardiacas más comunes, conseguir un diagnóstico de forma automática que sea fiable, utilizando tanto 12 como un número reducido o único de derivaciones, sigue presentándose como un desafío. Este aspecto cobra especial relevancia con el uso cada vez más extendido de dispositivos portátiles o wearables, los cuales están ganando un gran interés para la detección temprana y preventiva de enfermedades cardiacas, registrando normalmente un número reducido de derivaciones ECG. Dicho uso masivo les confiere un gran potencial para facilitar el cribado y seguimiento de distintas afecciones en una amplia variedad de escenarios, a pesar de registrar señales de peor calidad en comparación con equipos certificados para uso clínico. El principal reto con estos dispositivos es encontrar un equilibrio adecuado entre la sensibilidad y la especificidad en la detección de ritmos cardiacos susceptibles de ser patológicos. En consecuencia, es indispensable diseñar e implementar algoritmos precisos adecuados para dispositivos móviles o portátiles capaces de detectar distintas afecciones cardiacas en registros de ECG. Respecto las afecciones cardiacas menos comunes como el caso de la MCA, es necesario incrementar la sensibilidad en la detección durante los cribados intra-familiares realizados tras una MSC. Para ello, sería posible explorar biomarcadores propios a esta enfermedad obtenidos mediante técnicas de procesado de señales ECG, además de modelos de clasificación que hagan uso de ellos, contribuyendo así a reducir el número de casos de muerte súbita. En base a lo descrito anteriormente, la presente tesis estudia las posibilidades de diagnóstico basadas en técnicas de aprendizaje y clasificación automática en dos escenarios principales. El primero aborda la detección de la FA, así como un amplio abanico de otras patologías cardiacas comunes, donde proponemos y validamos distintos modelos de clasificación de bajo consumo computacional. Todo esto, utilizando extensas bases de datos de acceso abierto, y haciendo énfasis en enfoques de derivación única, ya que son los más utilizados en dispositivos móviles e inteligentes. El segundo escenario se centra en la detección de MCA mediante las 12 derivaciones estándar del ECG, donde proponemos y validamos nuevos biomarcadores y modelos de clasificación que tratan de incrementar la sensibilidad de los cribados intra-familiares realizados tras una MSC. Para ello, utilizamos una base de datos específica de la Unidad de Cardiopatías Familiares del Hospital Universitario y Politécnico La Fe de València. / [CA] Les malalties cardiovasculars són una de les principals causes de mortalitat i morbiditat en el món. Entre les arrítmies més comunes en adults destaca la Fibril·lació Auricular (FA), presentant una tendència de creixement molt significativa, sobretot en població d'edat avançada o amb trastorns d'obesitat. En l'altre extrem, ens trobem amb la Miocardiopatia Arritmogènica (MCA), considerada una malaltia rara amb una prevalença de 1:2000-5000 però amb gran afectació entre familiars directes, causant de mort sobtada cardíaca (MSC), i amb un diagnòstic clínic complicat. Més enllà de la FA o la MCA, existeix una àmplia varietat de patologies derivades d'una disfunció en l'activació i conducció elèctrica del cor. Per a totes elles, l'electrocardiograma (ECG) continua figurant com la primera i principal tècnica de diagnòstic clínic, sent una eina fonamental de cribratge i detecció de patologies relativament econòmica i àmpliament accessible. No obstant això, el diagnòstic precís a partir de la interpretació del ECG requereix de metges experimentats, sent aquesta una tasca que consumeix recursos, temps i que a més està subjecta a la variabilitat entre observadors. Respecte a les afeccions cardíaques més comunes, aconseguir un diagnòstic de manera automàtica que siga fiable, utilitzant tant 12 com un número reduït o únic de derivacions, continua presentant-se com un desafiament. Aquest aspecte cobra especial rellevància amb l'ús cada vegada més estés de dispositius portàtils o wearables, els quals estan guanyant un gran interés per a la detecció precoç i preventiva de malalties cardíaques, registrant normalment un nombre reduït de derivacions ECG. Aquest ús massiu els confereix un gran potencial per a facilitar el cribratge i seguiment de diferents afeccions en una àmplia varietat d'escenaris, malgrat registrar senyals de pitjor qualitat en comparació amb equips certificats per a ús clínic. El principal repte amb aquests dispositius és trobar un equilibri adequat entre la sensibilitat i l'especificitat en la detecció de ritmes cardíacs susceptibles de ser patològics. En conseqüència, és indispensable dissenyar i implementar algorismes precisos adequats per a dispositius mòbils o portàtils capaços de detectar diferents afeccions cardíaques en registres de ECG. Respecte les afeccions cardíaques menys comunes com el cas de la MCA, és necessari incrementar la sensibilitat en la detecció durant els cribratges intra-familiars realitzats després d'una MSC. Per a això, seria possible explorar biomarcadors propis a aquesta malaltia obtinguts mitjançant tècniques de processament de senyals ECG, a més de models de classificació que facen ús d'ells, contribuint així a reduir el nombre de casos de mort sobtada. Sobre la base del descrit anteriorment, la present tesi estudia les possibilitats de diagnòstic basades en tècniques d'aprenentatge i classificació automàtica en dos escenaris principals. El primer aborda la detecció de la FA, així com un ampli ventall d'altres patologies cardíaques comunes, on proposem i validem diferents models de classificació de baix consum computacional. Tot això, utilitzant extenses bases de dades d'accés obert, i fent èmfasi en enfocaments de derivació única, ja que són els més utilitzats en dispositius mòbils i intel·ligents. El segon escenari se centra en la detecció de MCA mitjançant les 12 derivacions estàndard de l'ECG, on proposem i validem nous biomarcadors i models de classificació que tracten d'incrementar la sensibilitat dels cribratges intra-familiars realitzats després d'una MSC. Per a això, utilitzem una base de dades específica de la Unitat de Cardiopaties Familiars de l'Hospital Universitari i Politècnic La Fe de València. / [EN] Cardiovascular diseases are one of the leading causes of mortality and morbidity worldwide. Atrial Fibrillation (AF) stands out among adults' most common arrhythmias, presenting a very significant growth trend, especially in the elderly population or those with obesity disorders. At the other extreme, we find Arrhythmogenic Cardiomyopathy (ACM), a rare disease with a prevalence of 1:2000-5000 but great affectation among direct relatives, causing sudden cardiac death (SCD), and with a complicated clinical diagnosis. Beyond AF or ACM, there is a wide variety of pathologies derived from dysfunctions in the activation or electrical conduction of the heart. For all of them, the electrocardiogram (ECG) continues to appear as the first and foremost clinical diagnostic technique, being a fundamental tool for screening and detecting pathologies that is relatively cheap and widely accessible. However, accurate diagnosis based on ECG interpretation requires experienced physicians, as this task consumes resources, time and is subject to variability between observers. For the most common cardiac conditions, achieving a reliable diagnosis automatically, using either 12 or a smaller or single number of leads, remains a challenge. This aspect is especially relevant with the increasingly widespread use of portable or wearable devices, which are gaining significant interest for the early and preventive detection of heart disease, typically recording a reduced number of ECG leads. Such massive use gives them great potential to facilitate screening and monitoring different conditions in different scenarios, despite registering signals of lower quality compared to equipment certified for clinical use. The main challenge with these devices is finding the right balance between sensitivity and specificity in detecting pathologic heart rhythms. Consequently, designing and implementing accurate algorithms suitable for mobile or portable devices capable of detecting different cardiac conditions in ECG recordings is essential. Concerning less common cardiac conditions such as the case of ACM, it is necessary to increase the sensitivity in detection during intra-family screenings carried out after an SCD. Hence, it would be possible to explore specific biomarkers to this disease obtained through ECG signal processing techniques, as well as classification models that use them, thus contributing to reduce the number of cases of sudden death. Based on the previously described, this thesis studies the diagnostic possibilities based on machine learning and classification techniques in two main scenarios. The first deals with detecting AF and a wide range of other common cardiac pathologies, where we propose and validate different classification models with low computational consumption. All this, using extensive open access databases, and emphasizing single-lead approaches, since they are the most used in mobile and smart devices. The second scenario focuses on detecting ACM using the standard 12-lead ECG, where we propose and validate new biomarkers and classification models that try to increase the sensitivity of intra-family screenings carried out after an MSC. For this task, we used a specific database of the Familial Cardiopathies Unit of the Hospital Universitario y Politécnico La Fe de València. / Jiménez Serrano, S. (2023). Desarrollo de nuevos marcadores y clasificadores de bajo coste computacional para identificar afecciones cardiacas en registros ECG [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/196826

A cardiomiopatia arritmogênica do ventrículo direito (CAVD) tem origem genética e é caracterizada pela substituição de células miocárdicas por tecido fibroadiposo. A doença tem uma prevalência aproximada de 1:3500, sendo mais frequentemente diagnosticada em indivíduos jovens, atletas e do sexo masculino. Atualmente, várias alterações genéticas associadas a CAVD foram descritas em 12 genes diferentes. No entanto, existem poucos estudos na literatura que descrevem o espectro mutacional da doença usando um painel abrangente de genes potencialmente causais, em populações diferentes das coortes descendentes de europeus. O sequenciamento de nova geração (NGS) como ferramenta para o diagnóstico molecular da doença, permite um avanço na correlação entre alterações genotípicas e fenotípicas e tem aportado potenciais benefícios que crescem juntamente com os desafios na sua interpretação. Além disso, o uso de hiPSCs como modelo in vitro de determinadas doenças cardíacas, permite avaliar especificamente a relação do genótipo com as diferentes consequências fenotípicas celulares da CAVD. Entretanto, os mecanismos moleculares da doença ainda são pouco esclarecidos e não há na literatura estudos que englobem ao mesmo tempo o perfil mutacional (com um painel extenso de genes) e estudo funcional das alterações encontradas com o uso de hiPSC-CMs. Esta tese teve como objetivo descrever a prevalência de variantes causais em genes associados à CAVD na população brasileira, e caracterizar, do ponto de vista funcional, os cardiomiócitos derivados de hiPSC (hiPSC-CMs) de pacientes com mutações identificadas, a fim de associar o perfil mutacional e a expressão fenotípica celular. Quarenta e sete indivíduos, não aparentados, sendo 38 (80,85%) pacientes do sexo masculino, idade média 40,2 ± 15,56 anos, com diagnóstico clínico de CAVD, foram submetidos ao sequenciamento de um painel genético relacionado à cardiomiopatias hereditárias, compreendendo os 12 genes previamente descritos como causadores de CAVD, utilizando sequenciamento de nova geração (NGS). As variantes foram interpretadas e classificadas de acordo com os critérios da ACMG. Variantes patogênicas ou provavelmente patogênicas foram encontradas em dezoito probandos (38,3%), com maior número de ocorrências no gene PKP2 (38,8%). Entre os 18 casos positivos, treze variantes diferentes foram encontradas, quatro delas novas variantes em genes desmossomais, sem descrição prévia na literatura. Variantes de significado incerto (VSI) foram encontradas em 16 pacientes. A presença de uma variante causal ocorreu em todos os probandos assintomáticos e foi significativamente associada a probandos com histórico familiar de morte súbita cardíaca abaixo de 35 anos. Para a modelagem celular da CAVD, foram geradas hiPSCs de dois pacientes a partir de células progenitoras de urina (UPCs) e fibroblastos, por transfecção episomal. O primeiro paciente possuía alteração missense no gene PKP2 e o segundo, uma inserção no gene DSC2. As hiPSCs foram caracterizadas quanto ao seu potencial de pluripotência e posteriormente diferenciadas em cardiomiócitos (hiPSC-CMs). Nossos resultados demonstraram diferenças fenotípicas significativas entre os CAVD-CMs comparados com os controle-CMs, como: reduções significativas de expressão das proteínas desmossomais e desmossomos estruturalmente alterados; presença de marcadores do acúmulo de gotículas lipídicas e regulação aumentada do fator de transcrição proadipogênico PPAR-gama; aumento de duração do potencial de campo (FPD) e do potencial de ação em 90% de repolarização (APD90); velocidade de condução mais lenta e uma força de contração menor. Em conclusão, este é o primeiro trabalho a caracterizar o perfil genético da CAVD, abrangendo todos os genes descritos até o momento relacionados à doença, na população brasileira. Os dados obtidos neste trabalho sugerem que, pacientes com história familiar de MSC ( < 35 anos) têm maior probabilidade de portar uma variante causal. Além disso, nossos achados sugerem que pacientes com alteração causal no gene PKP2 têm uma maior gravidade da apresentação fenotípica de arritmia. Nosso modelo celular, que contemplou células paciente-específicas com diferentes alterações das estudadas até o presente momento,sugere ser possível o estudo do efeito das alterações genéticas na CAVD e pode ser um acréscimo às ferramentas disponíveis para estudar o mecanismo desta doença complexa / Arrhythmogenic right ventricular cardiomyopathy (ARVC) has a genetic origin and is mainly characterized by the replacement of myocardial cells with fibroadipose tissue. The disease has a prevalence of approximately 1: 3.500, being more frequently diagnosed in young individuals, athletes and males. Currently, several mutations associated with ARVC have been described in 12 different genes. However, there are few studies in the literature that describe the mutational spectrum of the disease using a comprehensive panel of potentially causal genes in populations other than European-descent cohorts. Next Generation Sequencing (NGS) as a tool for molecular diagnosis of the disease allows an advance in the correlation between genotypic and clinical phenotypic aspects and has potential benefits that grow along with the challenges in its interpretation. In addition, the use of hiPSCs as an in vitro model of certain heart diseases, allows to specifically evaluate the relationship of the genotype with the different cellular phenotypic consequences of ARVC. However, the molecular mechanisms of the disease are still poorly understood and there are no studies in the literature that include both the mutational profile (with an extensive panel of genes) and functional study of different causal variants, with the use of hiPSC-CMs. The aim of this thesis was to describe the prevalence of causal variants in ARVC-associated genes in the Brazilian population, and to characterize, from a functional point of view, cardiomyocytes derived from hiPSC (hiPSC-CMs) from patients with identified mutations, in order to associate the mutational profile and cellular phenotypic expression. Forty-seven unrelated probands, 38 (80.85%) male, mean age 40.2 ± 15.56 years, with clinical diagnosis of ARVC, were submitted to a cardiomyopathy-related gene panel sequencing, comprising 12 genes, using next-generation sequencing (NGS). Variants were interpreted and classified according to the ACMG criteria. Pathogenic or Likely Pathogenic variants were found in eighteen probands (38.3%), with the largest number of occurrences in the PKP2 gene (38.8%). Among the 18 positive cases, thirteen different variants were found, four of them novel mutations in desmosomal genes, without previous description in the literature. Variants of uncertain significance (VUS) were found in 16 patients. The presence of a causal variant was present in all asymptomatic probands and was significantly associated with probands who have a family history of sudden cardiac death under 35 years. For the cellular modeling, from urinary progenitor cells (UPCs) and fibroblasts, hiPSCs from two patients were generated by episomal transfection. The first patient had a missense variant in the PKP2 gene, while the second had an insertion in the DSC2 gene. The hiPSCs were characterized for its pluripotency potential and subsequently differentiated into cardiomyocytes (hiPSC-CMs). Our results demonstrated significant phenotypic differences between the ARVC-CMs compared to the control-CMs, such as: significant reductions in the expression of desmosomal proteins and structurally altered desmosomes; presence of lipid droplet accumulation markers and increased regulation of the proadipogenic transcription factor PPAR-gamma; prolonged field potential duration (FPD) and action potential in 90% repolarization (APD90); slower conduction velocity and a lower active contraction force. In conclusion, this is the first work to characterize the genetic profile of ARVC, covering all genes described to date related to the disease, in the Brazilian population. The data obtained in this study suggests that patients with a family history of sudden cardiac death ( < 35 years) are more likely to carry a causal variant. In addition, our findings suggest that patients with causal variant in the PKP2 gene have a greater severity of the phenotypic presentation of arrhythmia. Our cellular model, which contemplated patient-specific cells with different causal variants of the previous studies, suggests that it is possible to study the effect of the genetic changes in ARVC, and may be an addition to the tools available to study the mechanism of this complex disease